Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

110 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to investigate effectiveness of stereotactic body radiotherapy in patients with bone metastatic disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases

NCT02622841

Neoplasm Metastasis

COMPLETED PHASE1/PHASE2

Stereotactic Body Radiotherapy Followed by Surgical Stabilization in Spinal Metastases

NCT05060653

Spinal Neoplasms Neoplasm Metastasis Radiosurgery +1 more

WITHDRAWN NA

Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases

NCT05575323

Spinal Metastases

RECRUITING NA

Intensity-modulated Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases

NCT02832765

Vertebral Bony Metastases

UNKNOWN PHASE2

Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow

NCT02145286

Metastatic Bone Lesion

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale: Bone metastases are a frequent distant manifestation of solid tumours, and many bone metastases are located in the spine. These patients mostly present with severe (back) pain which reduces quality of life. The primary treatment for pain management is a single-fraction low dose external beam radiation therapy (EBRT), effective in achieving pain reduction in around 60% of patients, of whom 0-23% experience complete pain response. Recently, there is growing evidence that Stereotactic Body Radiotherapy (SBRT) achieves a much higher pain response due to the higher dose administered. In retrospective and a few prospective case series, SBRT for spinal, and also non-spinal metastases has been demonstrated to be safe, and efficacious. However, no randomized controlled trials have been performed.

Objective: To study whether the pain response after three months in patients with osseous metastatic disease increases after SBRT in comparison to low dose EBRT.

Study design: Randomized controlled trial, the VERTICAL study, nested within the PRESENT cohort.

Study population: Eligible patients are MRI-compatible patients with radiographic evidence of bone metastases at the radiotherapy department. Fifty-five patients are recruited in both control and intervention arm.

Intervention: Patients will undergo MRI-based, cone beam CT-guided SBRT and will receive a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).

Main study parameters/endpoints: The primary endpoint is pain control at three months after radiotherapy. Secondary outcomes are, among others, the occurrence of vertebral compression fracture (VCF) and radiation-induced myelopathy, local tumour control and evaluation of quality of life.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Metastases Bone Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Stereotactic Body Radiotherapy

MRI-based, cone beam CT-guided SBRT delivery of a single dose of 18 Gray (Gy) on the visible metastasis, and 8 Gy on the bony compartment containing the metastasis (e.g. the affected vertebra or pedicle).

Group Type EXPERIMENTAL

Stereotactic Body Radiotherapy

Intervention Type RADIATION

Conventional Radiotherapy

Delivery of a single fraction of 8 Gy using virtual simulation

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Stereotactic Body Radiotherapy

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Stereotactic Radiosurgery

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Radiographic evidence of bone metastases
* For spinal lesions; per lesion no more than 3 consecutive spine segments involved with one unaffected vertebral body above and below
* No more than 2 painful lesions needing treatment
* Histologic proof of malignancy
* No compression of spinal cord
* No or mild neurological signs (i.e. radiculopathy, dermatomal sensory change, and muscle strength of involved extremity is Medical Research Council (MRC) 4/5
* Medically inoperable or patient refused surgery
* Karnofsky performance score (KPS) \> 50
* Numeric rating scale (NRS) \> 3
* Age \> 18 years
* Written informed consent
* Filling out PRESENT-questionnaires

Exclusion Criteria

* Lesion in C1 or C2
* Radio-sensitive histology such as multiple myeloma, lymphoma, small cell, germ cell
* Spinal MRI cannot be completed for any reason (in according with the MRI protocol of the Department of Radiology)
* Impossible to delineate metastasis and organs at risk (OAR) due to artifacts on CT or MRI from previous surgical stabilization
* Unable to undergo SBRT treatment, according to treating doctor's opinion
* Epidural disease
* Severe, worsening or progressive neurological deficit
* Unstable lesion requiring surgical stabilization
* Patient with \< 3 months life expectancy
* Previous EBRT or SBRT to same level
* Chemotherapy or systemic radionuclide delivery within 24 hours before and after SBRT

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No